Skip to main content
Top
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Clinical significance of programmed cell death 4 expression in malignant progression of human nasal inverted papillomas

Authors: Yan Wang, Lingling Ding, Xia Zhang, Miaoqing Zhao, Zhonghua Qu, Shanying Huang, Yun Zhang, Yanzhong Li, Fei Gao

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

Programmed cell death 4 (PDCD4) is a novel tumor suppressor gene that can inhibit tumor neoplastic transformation and progression in cultured cells and gene knock-out mouse models. Lost or decreased PDCD4 expression has been associated with progression and prognosis of multiple types of human tumors. However, the expression and clinical significance of PDCD4 in nasal inverted papillomas (NIPs) has not been investigated. We compared PDCD4 expression in 64 samples of NIPs, 23 of associated squamous cell carcinomas (SCCs), and 19 normal nasal samples at mRNA and protein levels by RT-PCR, western blot analysis, and immunohistochemistry. PDCD4 mRNA expression was reduced in 52% of NIP frozen samples (13/25), and the protein level was diminished in 56.3% of samples (36/64) as compared with 19 normal nasal samples, which expressed high levels of PDCD4 mRNA and protein. Furthermore, altered expression of PDCD4 was associated with the clinicopathological features Krouse stage and dysplasia. Importantly, we found a strong negative correlation of PDCD4 expression and Ki-67 labeling index in NIPs (r = −0.6645, p < 0.001). In addition, the 3 tissue-sample groups significantly differed in PDCD4 expression and Ki-67 labeling index. Thus, PDCD4 expression may play a key role in pre-cancerous lesions of human NIPs and may help predict malignant progression from benign nasal tumors to associated SCC.
Literature
1.
go back to reference Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS. Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol. 2007;121:857–64.PubMedCrossRef Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS. Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol. 2007;121:857–64.PubMedCrossRef
2.
go back to reference Heathcote KJ, Nair SB. The impact of modern techniques on the recurrence rate of inverted papilloma treated by endonasal surgery. Rhinology. 2009;47:339–44.PubMed Heathcote KJ, Nair SB. The impact of modern techniques on the recurrence rate of inverted papilloma treated by endonasal surgery. Rhinology. 2009;47:339–44.PubMed
3.
go back to reference Reh DD, Lane AP. The role of endoscopic sinus surgery in the management of sinonasal inverted papilloma. Curr Opin Otolaryngol Head Neck Surg. 2009;17:6–10.PubMedCrossRef Reh DD, Lane AP. The role of endoscopic sinus surgery in the management of sinonasal inverted papilloma. Curr Opin Otolaryngol Head Neck Surg. 2009;17:6–10.PubMedCrossRef
4.
go back to reference Anari S, Carrie S. Sinonasal inverted papilloma: narrative review. J Laryngol Otol. 2010;124:705–15.PubMedCrossRef Anari S, Carrie S. Sinonasal inverted papilloma: narrative review. J Laryngol Otol. 2010;124:705–15.PubMedCrossRef
5.
go back to reference Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell. 2009;101:309–17.PubMedCrossRef Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell. 2009;101:309–17.PubMedCrossRef
6.
go back to reference Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999;96:14037–42.PubMedCrossRef Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999;96:14037–42.PubMedCrossRef
7.
go back to reference Dhar A, Young MR, Colburn NH. The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem. 2002;234–235:185–93.PubMedCrossRef Dhar A, Young MR, Colburn NH. The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem. 2002;234–235:185–93.PubMedCrossRef
8.
go back to reference Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003;22:3712–20.PubMedCrossRef Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003;22:3712–20.PubMedCrossRef
9.
go back to reference Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005;65:6034–41.PubMedCrossRef Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005;65:6034–41.PubMedCrossRef
10.
go back to reference Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006;26:1297–306.PubMedCrossRef Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006;26:1297–306.PubMedCrossRef
11.
go back to reference Göke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004;287:C1541–6.PubMedCrossRef Göke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004;287:C1541–6.PubMedCrossRef
12.
go back to reference Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 2004;3:103–10.PubMed Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther. 2004;3:103–10.PubMed
13.
go back to reference Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F, et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep. 2007;17:123–8.PubMed Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F, et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep. 2007;17:123–8.PubMed
14.
go back to reference Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009;100:1408–13.PubMedCrossRef Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009;100:1408–13.PubMedCrossRef
15.
go back to reference Ma G, Guo KJ, Zhang H, Ozaki I, Matsuhashi S, Zheng XY, et al. Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005;27:597–600.PubMed Ma G, Guo KJ, Zhang H, Ozaki I, Matsuhashi S, Zheng XY, et al. Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005;27:597–600.PubMed
16.
go back to reference Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003;200:640–6.PubMedCrossRef Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003;200:640–6.PubMedCrossRef
17.
go back to reference Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 2006;25:6101–12.PubMedCrossRef Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 2006;25:6101–12.PubMedCrossRef
18.
go back to reference Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene. 2004;23:8135–45.PubMedCrossRef Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene. 2004;23:8135–45.PubMedCrossRef
19.
go back to reference Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007;110:1697–707.PubMedCrossRef Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007;110:1697–707.PubMedCrossRef
20.
go back to reference Ding L, Zhang X, Zhao M, Qu Z, Huang S, Dong M, et al. An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors. Med Oncol. 2011. [Epub ahead of print]. Ding L, Zhang X, Zhao M, Qu Z, Huang S, Dong M, et al. An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors. Med Oncol. 2011. [Epub ahead of print].
21.
22.
go back to reference Chadderton T, Wilson C, Bewick M, Gluck S. Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR’s and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand). 1997;43:1227–34. Chadderton T, Wilson C, Bewick M, Gluck S. Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR’s and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand). 1997;43:1227–34.
23.
go back to reference Culley DE, Kovacik WP Jr, Brockman FJ, Zhang W. Optimization of RNA isolation from the archaebacterium Methanosarcina barkeri and validation for oligonucleotide microarray analysis. J Microbiol Methods. 2006;67:36–43.PubMedCrossRef Culley DE, Kovacik WP Jr, Brockman FJ, Zhang W. Optimization of RNA isolation from the archaebacterium Methanosarcina barkeri and validation for oligonucleotide microarray analysis. J Microbiol Methods. 2006;67:36–43.PubMedCrossRef
24.
go back to reference Bura M, Seiwerth S, Vladika I, Perović D, Nagy P, Corić M, et al. Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. Coll Antropol. 2007;31:545–9.PubMed Bura M, Seiwerth S, Vladika I, Perović D, Nagy P, Corić M, et al. Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. Coll Antropol. 2007;31:545–9.PubMed
25.
go back to reference Carta F, Verillaud B, Herman P. Role of endoscopic approach in the management of inverted papilloma. Curr Opin Otolaryngol Head Neck Surg. 2011;19:21–4.PubMedCrossRef Carta F, Verillaud B, Herman P. Role of endoscopic approach in the management of inverted papilloma. Curr Opin Otolaryngol Head Neck Surg. 2011;19:21–4.PubMedCrossRef
26.
go back to reference Sandison A. Common head and neck cases in our consultation referrals: diagnostic dilemmas in inverted papilloma. Head Neck Pathol. 2009;3:260–2.PubMedCrossRef Sandison A. Common head and neck cases in our consultation referrals: diagnostic dilemmas in inverted papilloma. Head Neck Pathol. 2009;3:260–2.PubMedCrossRef
27.
go back to reference Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79:313–20.PubMedCrossRef Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79:313–20.PubMedCrossRef
28.
go back to reference Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, Bocus P, et al. Programmed cell death 4 (PDCD4) expression during multistep Barrett’s carcinogenesis. J Clin Pathol. 2010;63(8):692–6.PubMedCrossRef Fassan M, Pizzi M, Battaglia G, Giacomelli L, Parente P, Bocus P, et al. Programmed cell death 4 (PDCD4) expression during multistep Barrett’s carcinogenesis. J Clin Pathol. 2010;63(8):692–6.PubMedCrossRef
29.
go back to reference Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 2010;36:1089–95.PubMed Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 2010;36:1089–95.PubMed
30.
go back to reference Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006;314:428–9.CrossRef Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006;314:428–9.CrossRef
31.
go back to reference Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, et al. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3 K/Akt signaling pathway. Mol Diagn Ther. 2010;14:155–61.PubMedCrossRef Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, et al. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3 K/Akt signaling pathway. Mol Diagn Ther. 2010;14:155–61.PubMedCrossRef
32.
go back to reference Schlichter U, Kattmann D, Appl H, Miethe J, Brehmer-Fastnacht A, Klempnauer KH. Identification of the myb-inducible promoter of the chicken Pdcd4 gene. Biochim Biophys Acta. 2001;1520:99–104.PubMedCrossRef Schlichter U, Kattmann D, Appl H, Miethe J, Brehmer-Fastnacht A, Klempnauer KH. Identification of the myb-inducible promoter of the chicken Pdcd4 gene. Biochim Biophys Acta. 2001;1520:99–104.PubMedCrossRef
33.
go back to reference Fan H, Zhao Z, Quan Y, Xu J, Zhang J, Xie W. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721. Eur J Gastroenterol Hepatol. 2007;19:952–61.PubMedCrossRef Fan H, Zhao Z, Quan Y, Xu J, Zhang J, Xie W. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721. Eur J Gastroenterol Hepatol. 2007;19:952–61.PubMedCrossRef
34.
go back to reference Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo C, et al. PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis. J Cell Mol Med. 2009;13:4257–67.PubMedCrossRef Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo C, et al. PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis. J Cell Mol Med. 2009;13:4257–67.PubMedCrossRef
Metadata
Title
Clinical significance of programmed cell death 4 expression in malignant progression of human nasal inverted papillomas
Authors
Yan Wang
Lingling Ding
Xia Zhang
Miaoqing Zhao
Zhonghua Qu
Shanying Huang
Yun Zhang
Yanzhong Li
Fei Gao
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0185-0

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue